Skip to main content
. 2022 Jan 24;10(1):e003024. doi: 10.1136/jitc-2021-003024

Figure 3.

Figure 3

Long-term OS in clinical trials with immune checkpoint inhibitor and targeted therapies in patients with advanced melanoma.39 Data presented represent first-line treatment options, with the exception of those for IL-2 and pooled ipilimumab, for patients with melanoma; results will vary by tumor type. Permissions to use figures: licensed under the Creative Commons Attribution V.4.0 License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by/4.0/). IL, interleukin; OS, overall survival.